Sentynl Therapeutics, Inc., a wholly-owned subsidiary of Zydus Lifesciences Limited , has entered into an option and license agreement with Mereo BioPharma Group plc for alvelestat. The agreement grants Sentynl the exclusive right to acquire a license to commercialize alvelestat for Alpha-1 Antitrypsin Deficiency-Associated Lung Disease (AATD-LD) in the United States, expanding its rare disease portfolio with a potential first-in-class oral treatment. Mereo BioPharma will retain commercial rights in the rest of the world and lead the global Phase 3 study and regulatory interactions until completion. This partnership addresses a significant unmet need in a rare genetic respiratory disease affecting an estimated 50,000–80,000 individuals in the United States.

The financial terms of the agreement include a non-refundable option fee paid by Sentynl to Mereo. Upon exercise of the option, Mereo is eligible to receive up to $40 million in upfront and R&D payments until New Drug Application (NDA) filing. Additionally, Mereo will receive double-digit tiered royalties on U.S. net sales of alvelestat. Sentynl also acquires global manufacturing rights for alvelestat for AATD-LD under this arrangement. The companies plan to collaborate during the short option period to refine the Phase 3 study design and advance manufacturing, with the Phase 3 program potentially initiating in early 2027.

Key Agreement Terms

Alvelestat is a novel oral small molecule designed to specifically inhibit neutrophil elastase, a key enzyme involved in inflammation and lung tissue destruction. It has received Orphan Drug Designation for AATD-LD from both the European Commission and the FDA, as well as Fast Track designation from the FDA. The safety and tolerability profile of alvelestat has been established through clinical trials in over 1,000 patients with various respiratory diseases, including AATD-LD, COPD, bronchiectasis, cystic fibrosis, COVID-19, and bronchiolitis obliterans syndrome. Positive efficacy data from two Phase 2 studies backs the preparation for the global Phase 3 study.

Dr. Sharvil P. Patel, Managing Director of Zydus Lifesciences Limited, stated that the partnership marks a pivotal moment for Sentynl's rare disease strategy, adding a highly promising candidate that could address significant unmet needs. Matt Heck, Chief Executive Officer of Sentynl Therapeutics, noted that alvelestat offers an opportunity to improve upon the current standard of care, which often relies on demanding intravenous treatments. Denise Scots-Knight, Chief Executive Officer of Mereo BioPharma, expressed pleasure in partnering with Sentynl, citing its commitment to rare diseases and established commercial infrastructure as ideal for advancing alvelestat.

Zydus Lifesciences has received final approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Indocyanine Green for Injection, USP, 25 mg/vial. The regulator has designated the application as a Competitive Generic Therapy (CGT), granting the company eligibility for 180 days of market exclusivity upon first commercial marketing. This approval strengthens Zydus' position in the US generics market, particularly in the complex imaging agent segment.

The approved product is a sterile lyophilised powder for reconstitution, supplied as a kit with single-patient-use vials of Indocyanine Green and Sterile Water for Injection. It serves as a generic equivalent to Diagnostic Green LLC’s reference listed drug, IC-Green®. Indocyanine Green is an optical imaging agent used for fluorescence imaging of vessels, blood flow, and tissue perfusion during vascular, gastrointestinal, organ transplant, and reconstructive surgeries. It is also indicated for imaging extrahepatic biliary ducts, lymphatic mapping in cervical and uterine cancer patients, and ophthalmic angiography in adults and paediatric patients aged one month and older.

Key Approval Details

The following table outlines the specifics of the regulatory milestone:

Market Potential and Portfolio Growth

The brand product, IC-Green®, reported annual sales of approximately USD 125.8 mn in the United States, representing a 61.0% growth, with volumes rising 27.1% to 0.64 mn units, according to IQVIA MAT June-2026 data. Zydus plans to launch the product shortly to trigger the 180-day exclusivity period. The product will be manufactured at the group’s USFDA-approved injectable plant in Jarod and marketed in the US by Zydus Pharmaceuticals (USA) Inc.

This approval adds to Zydus’ growing portfolio of complex injectables and imaging products. As of June 30, 2026, the group holds 445 USFDA approvals and has filed 513 ANDAs. Dr. Sharvil Patel, Managing Director of Zydus Lifesciences Limited, noted that securing approval for such a complex product reflects the company’s capabilities in chromophore purity and lyophilisation control. He emphasized that this development advances their goal of making essential diagnostics more accessible while strengthening their presence in the functional dye segment.

What the Numbers Show

The significant growth in the brand product’s sales volume (27.1%) and value (61.0%) indicates a robust and expanding addressable market for indocyanine green in the US. By entering with CGT exclusivity, Zydus positions itself to capture a substantial share of this growing niche before other generic competitors can enter. This move aligns with the company’s broader strategy of leveraging internal formulation expertise combined with external partnerships to develop complex generics, thereby diversifying revenue streams beyond standard therapeutic categories.